226 related articles for article (PubMed ID: 26099674)
1. Fludeoxyglucose F 18 PET-Computed Tomography: Management Changes Effecting Patient Outcomes in Gynecologic Malignancies.
Brunetti JC
PET Clin; 2015 Jul; 10(3):395-409. PubMed ID: 26099674
[TBL] [Abstract][Full Text] [Related]
2. FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes.
Parikh U; Marcus C; Sarangi R; Taghipour M; Subramaniam RM
PET Clin; 2015 Jul; 10(3):327-43. PubMed ID: 26099670
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of gynecologic cancer with MR imaging, 18F-FDG PET/CT, and PET/MR imaging.
Lee SI; Catalano OA; Dehdashti F
J Nucl Med; 2015 Mar; 56(3):436-43. PubMed ID: 25635136
[TBL] [Abstract][Full Text] [Related]
4. PET with Fluorodeoxyglucose F 18/Computed Tomography in the Clinical Management and Patient Outcomes of Esophageal Cancer.
Kwee RM; Marcus C; Sheikhbahaei S; Subramaniam RM
PET Clin; 2015 Apr; 10(2):197-205. PubMed ID: 25829086
[TBL] [Abstract][Full Text] [Related]
5. [¹⁸F]fluorodeoxyglucose PET/computed tomography in breast cancer and gynecologic cancers: a literature review.
Hildebrandt MG; Kodahl AR; Teilmann-Jørgensen D; Mogensen O; Jensen PT
PET Clin; 2015 Jan; 10(1):89-104. PubMed ID: 25455882
[TBL] [Abstract][Full Text] [Related]
6. Molecular Imaging and Precision Medicine in Uterine and Ovarian Cancers.
Zukotynski KA; Kim CK
PET Clin; 2017 Oct; 12(4):393-405. PubMed ID: 28867111
[TBL] [Abstract][Full Text] [Related]
7. Diuretic 18F-Fluorodeoxyglucose PET/Computed Tomography in Evaluation of Genitourinary Malignancies.
Agarwal KK; Roy SG; Kumar R
PET Clin; 2016 Jan; 11(1):39-46. PubMed ID: 26590442
[TBL] [Abstract][Full Text] [Related]
8. FDG-PET/CT as a molecular biomarker in ovarian cancer.
Nowosinska E; Avril S; Murray I; Szyszko T; Avril N
Cancer Biomark; 2010-2011; 8(4-5):167-75. PubMed ID: 22045351
[TBL] [Abstract][Full Text] [Related]
9. PET/Computed Tomography and Patient Outcomes in Melanoma.
Rohren EM
PET Clin; 2015 Apr; 10(2):243-54. PubMed ID: 25829089
[TBL] [Abstract][Full Text] [Related]
10. (18)F-Flourodeoxy-Glucose PET/Computed Tomography in Brain Tumors: Value to Patient Management and Survival Outcomes.
Wray R; Solnes L; Mena E; Meoded A; Subramaniam RM
PET Clin; 2015 Jul; 10(3):423-30. PubMed ID: 26099676
[TBL] [Abstract][Full Text] [Related]
11. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer.
Laurens ST; Oyen WJ
PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671
[TBL] [Abstract][Full Text] [Related]
12. [18F]fludeoxyglucose positron emission tomography and computed tomography as a prognostic tool before liver transplantation, resection, and loco-ablative therapies for hepatocellular carcinoma.
Asman Y; Evenson AR; Even-Sapir E; Shibolet O
Liver Transpl; 2015 May; 21(5):572-80. PubMed ID: 25644857
[TBL] [Abstract][Full Text] [Related]
13. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET.
Torizuka T; Kanno T; Futatsubashi M; Okada H; Yoshikawa E; Nakamura F; Takekuma M; Maeda M; Ouchi Y
J Nucl Med; 2003 Jul; 44(7):1051-6. PubMed ID: 12843219
[TBL] [Abstract][Full Text] [Related]
14. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas.
Sheikhbahaei S; Marcus C; Hafezi-Nejad N; Taghipour M; Subramaniam RM
PET Clin; 2015 Jul; 10(3):375-93. PubMed ID: 26099673
[TBL] [Abstract][Full Text] [Related]
15. Gynecological cancers.
Avril N; Gourtsoyianni S; Reznek R
Methods Mol Biol; 2011; 727():171-89. PubMed ID: 21331934
[TBL] [Abstract][Full Text] [Related]
16. Established, emerging and future applications of FDG-PET/CT in the uterine cancer.
Kitajima K; Murakami K; Kaji Y; Sakamoto S; Sugimura K
Clin Radiol; 2011 Apr; 66(4):297-307. PubMed ID: 21356392
[TBL] [Abstract][Full Text] [Related]
17. FDG-PET/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy.
De Iaco P; Musto A; Orazi L; Zamagni C; Rosati M; Allegri V; Cacciari N; Al-Nahhas A; Rubello D; Venturoli S; Fanti S
Eur J Radiol; 2011 Nov; 80(2):e98-103. PubMed ID: 20688446
[TBL] [Abstract][Full Text] [Related]
18. Metabolic Tumor Volume on 18F-FDG PET/CT Improves Preoperative Identification of High-Risk Endometrial Carcinoma Patients.
Husby JA; Reitan BC; Biermann M; Trovik J; Bjørge L; Magnussen IJ; Salvesen ØO; Salvesen HB; Haldorsen IS
J Nucl Med; 2015 Aug; 56(8):1191-8. PubMed ID: 26045311
[TBL] [Abstract][Full Text] [Related]
19. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
Salem SS; Shahin MA
Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
[TBL] [Abstract][Full Text] [Related]
20. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
